Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Aug 11, 2021 (5 years ago)

Naproxen Sodum Tablets USP 220 mg

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Naproxen Sodum Tablets USP 220 mg, (Caplet), Manufactured by: Granules India Limited, Sy.No. 160/A, 161/E, 162, &174/A, Gagillapur Village, Dundigal-Gandimalsamma Monday, Medchai-Maikhajgir District - 500043, Telangana, INDIA. NDC 62207-762-36

Affected NDC 62207-0762-36

Compare with the code on your package — it is the most precise check available.

Drug: Naproxen Category: Pain Relief & OTC Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Naproxen Sodium
NDC 62207-0762
220 mg/1 Tablet, Film Coated Granules India Limited DRUG FOR FURTHER PROCESSING
Recalling firm
Granules USA, Inc.
NDC code
62207-762-36
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0777-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Naproxen recalls

See all
Class II · Moderate risk

Naproxen Oral Suspension

Chemical contamination; presence of lead and lithium above specification

Ongoing Chemical / undeclared Acella Pharmaceuticals, LLC NDC 42192-619-16 D-0523-2026
Class II · Moderate risk

Naproxen Tablets

Labeling: Label Mix-Up-Indomethacin bottles may be labeled as Naproxen

Ongoing Labeling / mix-up Glenmark Pharmaceuticals Inc., USA NDC 68462-188-01 D-0124-2024

Other cgmp deviation recalls from 2021

All cgmp deviation recalls